Supreme Court Lets Merck Loss In Fosamax Case Stand

Law360, New York (October 17, 2005, 12:00 AM EDT) -- In a setback for Merck & Co., the U.S. Supreme Court has rejected the company’s appeal of a decision that shaved a decade off the patent for blockbuster osteoporosis drug Fosamax.

The decision lets stand a ruling by the U.S. Court of Appeals for the Federal Circuit that the patent on the once-weekly osteoporosis drug Fosamax will expire in February 2008, a decade earlier than expected.

The court denied Merck's appeal without comment. Chief Justice John Roberts and Justices Sandra Day O'Connor and Stephen Breyer had...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.